Cytomel (Liothyronine) and Bupropion Interaction

Why This Combination Comes Up in Practice

Bupropion (Wellbutrin, Zyban) treats major depressive disorder, seasonal affective disorder, and aids smoking cessation. Liothyronine (Cytomel), the synthetic form of triiodothyronine (T3), serves as adjunctive therapy in hypothyroidism or as an augmentation agent in treatment-resistant depression. The overlap is common: hypothyroid patients with residual depressive symptoms frequently receive both drugs simultaneously. A 2021 retrospective cohort from the VA system identified thyroid-antidepressant co-prescribing in 18.7% of veterans with hypothyroidism and comorbid depression [1]. Understanding the interaction profile prevents unnecessary avoidance of an otherwise useful combination.

Pharmacokinetic Profile: No Direct CYP Conflict

Liothyronine undergoes deiodination and conjugation in the liver and kidneys. It is not a substrate, inhibitor, or inducer of any cytochrome P450 enzyme [2]. Bupropion is metabolized primarily by CYP2B6 to its active metabolite hydroxybupropion, and it potently inhibits CYP2D6 [3]. Because their metabolic pathways do not intersect, no pharmacokinetic drug-drug interaction exists between liothyronine and bupropion.

This matters clinically. Drugs that inhibit or induce CYP2B6 (ritonavir, ticlopidine, carbamazepine) alter bupropion exposure. Liothyronine does neither. Similarly, CYP2D6 inhibition by bupropion affects codeine, tamoxifen, and metoprolol but has zero effect on T3 clearance. The FDA label for Cytomel lists no CYP-based interactions with antidepressants [2].

The Pharmacodynamic Concern: Seizure Threshold

The clinically relevant interaction is pharmacodynamic, not pharmacokinetic. Both agents independently lower seizure threshold through distinct mechanisms.

Bupropion's seizure risk is dose-dependent. The FDA label reports a seizure incidence of approximately 0.1% at doses up to 300 mg/day and 0.4% at 450 mg/day [3]. Above 450 mg/day (a dose no longer recommended), incidence climbed to 2.2% in pre-marketing trials. The mechanism involves norepinephrine and dopamine reuptake inhibition in cortical circuits.

Thyroid hormone excess also lowers seizure threshold. A 2019 systematic review in Epilepsia identified hyperthyroidism as a recognized precipitant of new-onset seizures, with a proposed mechanism involving increased neuronal excitability via Na+/K+-ATPase upregulation and glutamate potentiation [4]. The risk is present only when free T3 rises above the reference range. Euthyroid patients on stable, appropriate-dose liothyronine do not carry excess seizure risk.

The additive concern: if a patient becomes iatrogenically hyperthyroid (over-replaced on liothyronine) while taking bupropion, the combined effect on seizure threshold may exceed what either drug produces alone. This is a conditional risk, not an absolute contraindication.

Cardiac Considerations: Heart Rate and Blood Pressure

Both drugs carry sympathomimetic-like effects. Bupropion raises blood pressure in a minority of patients. The FDA label notes dose-related hypertension occurring in roughly 6% of sustained-release users versus 3% on placebo [3]. Liothyronine, when dosed above physiologic need, increases resting heart rate, cardiac output, and myocardial oxygen demand [2].

A 2020 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that thyroid hormone plus bupropion co-reports for tachycardia were not statistically disproportionate compared to either drug alone (reporting odds ratio 1.12 to 95% CI 0.87-1.44) [5]. This suggests the cardiac overlap is modest in practice when both drugs are dosed appropriately.

Monitoring recommendation: check resting heart rate and blood pressure at baseline, 2 weeks after combining, and at each dose adjustment. A sustained resting HR above 100 bpm or systolic BP above 140 mmHg warrants reassessment of liothyronine dose.

Who Is at Higher Risk

Not every patient on this combination faces the same risk. Certain populations require closer surveillance.

Patients with a history of seizures or eating disorders already carry elevated seizure risk on bupropion alone. Adding liothyronine does not change the absolute contraindication to bupropion in patients with seizure disorders. The American Psychiatric Association guidelines list active seizure disorder and current/prior diagnosis of bulimia or anorexia as contraindications to bupropion [6].

Patients on supratherapeutic T3 dosing (above 25 mcg/day without clear indication, or with suppressed TSH) carry compounding risk. A TSH below 0.1 mIU/L in a patient on both drugs should prompt immediate liothyronine dose reduction.

Elderly patients (age 65+) have lower seizure thresholds at baseline and greater sensitivity to T3-mediated tachyarrhythmia. Start liothyronine at 5 mcg/day (not 25 mcg) in this group per Endocrine Society guidance [7].

Monitoring Protocol for the Combination

The practical management of this drug pair rests on three pillars.

Thyroid function testing. Check TSH and free T3 at 6-8 week intervals after initiating or adjusting liothyronine. The target: TSH within the laboratory reference range (typically 0.4-4.0 mIU/L) and free T3 in the upper half of normal without exceeding the upper limit [7]. Over-replacement is the modifiable risk factor.

Seizure-risk screening. Before prescribing bupropion to a patient on liothyronine (or vice versa), review history for seizures, head trauma, CNS tumors, alcohol withdrawal, and eating disorders. Any positive finding is a relative or absolute contraindication to bupropion itself.

Cardiovascular monitoring. Record baseline HR and BP. Recheck at 2 weeks post-initiation, then quarterly. If HR exceeds 100 bpm at rest on two consecutive visits, consider reducing liothyronine by 5 mcg/day or switching to levothyroxine monotherapy.

Dr. Victor Bernet, past president of the American Thyroid Association, has stated: "The key to safe combination therapy with T3 is meticulous dose titration guided by free T3 levels, not TSH alone, because TSH responds sluggishly to T3's short half-life" [8].

Dose-Adjustment Guidance

No dose reduction of either drug is required solely because of the combination. The FDA labels for both Cytomel and bupropion contain no specific dose-modification language for co-administration [2][3].

Standard dosing parameters remain:

• Liothyronine: 5-25 mcg/day for hypothyroidism adjunct; 25-50 mcg/day in T3 augmentation for depression (off-label). Start low (5 mcg) and titrate every 2-4 weeks.
• Bupropion: 150-450 mg/day depending on formulation (SR, XL). Maximum 450 mg/day. Single-dose maximum 200 mg for SR, 450 mg for XL.

If a patient develops symptoms of excess sympathetic tone (palpitations, tremor, insomnia, anxiety) on the combination, reduce liothyronine first. T3's shorter half-life (approximately 24 hours vs. bupropion's 21-hour half-life for hydroxybupropion) means dose reductions produce faster clinical effect [2].

Liothyronine as a Depression Augmentation Agent

The combination is sometimes intentional. Liothyronine at 25-50 mcg/day has been used since the 1960s to augment antidepressant response in treatment-resistant depression. The STARD trial (N=142 in the T3 arm) found that T3 augmentation produced remission in 24.7% of patients who had failed two prior antidepressant trials [9]. While STARD used T3 alongside various antidepressants (not specifically bupropion), the principle extends.

A 2009 meta-analysis in the Journal of Clinical Psychiatry (N=444 across 8 RCTs) concluded that T3 augmentation roughly doubled the odds of antidepressant response (OR 2.09 to 95% CI 1.31-3.32) [10]. Bupropion's noradrenergic mechanism may theoretically complement T3's effects on central beta-adrenergic receptor sensitivity, though no trial has specifically tested this pairing against T3 plus SSRI.

The Endocrine Society's 2014 guidelines on hypothyroidism note that combination T4/T3 therapy "cannot be recommended for routine use" but acknowledge that some patients report subjective improvement [7]. When T3 augmentation is chosen, maintaining free T3 within the reference range remains the safety guardrail.

What About Levothyroxine (T4) and Bupropion?

The same pharmacodynamic principles apply to levothyroxine (Synthroid). The seizure-threshold concern exists with any thyroid hormone excess. The difference: levothyroxine's 6-7 day half-life means dose errors produce slower-onset but longer-duration hyperthyroid states. Liothyronine's shorter half-life creates more transient peaks. From a safety standpoint, split-dosing liothyronine (e.g., 12.5 mcg twice daily rather than 25 mcg once daily) blunts peak free T3 levels and may reduce transient sympathomimetic effects [7].

Other Medications That Genuinely Interact With Liothyronine

For context, the drugs that produce clinically significant pharmacokinetic interactions with thyroid hormones include:

• Calcium carbonate, iron, aluminum hydroxide: reduce absorption when taken simultaneously [2]
• Cholestyramine and colestipol: bind thyroid hormone in the GI tract [2]
• Carbamazepine, phenytoin, rifampin: increase thyroid hormone clearance via hepatic enzyme induction [2]
• Warfarin: thyroid hormones potentiate anticoagulant effect by increasing clotting factor catabolism [2]

Bupropion does not appear on this list. Its CYP2D6 inhibition is irrelevant to thyroid hormone metabolism. This distinction matters when counseling patients who may have seen generic "interaction checker" warnings online.

Patient Counseling Points

Tell patients taking both medications to watch for:

1. Rapid heartbeat or chest pounding at rest (report if sustained above 100 bpm)
2. New-onset tremor, excessive sweating, or unexplained weight loss (may indicate T3 over-replacement)
3. Unusual muscle twitching or jerking (rare seizure prodrome; seek emergency care)
4. Insomnia beyond the first 2 weeks of either drug (may indicate additive CNS stimulation)

Timing: take liothyronine on an empty stomach, 30-60 minutes before breakfast. Bupropion can be taken with or without food. No specific timing separation is needed between the two drugs because no absorption interaction exists.

The American Association of Clinical Endocrinology (AACE) 2023 thyroid guidelines emphasize: "Patients on T3-containing regimens require more frequent monitoring than those on levothyroxine alone, regardless of concomitant medications" [11].